| HIV Infections
Biktarvy vs Stribild
Side-by-side clinical, coverage, and cost comparison for hiv infections.Deep comparison between: Biktarvy vs Stribild with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsStribild has a higher rate of injection site reactions vs Biktarvy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Stribild but not Biktarvy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Biktarvy
Stribild
At A Glance
Oral
Daily
INSTI + NRTI combination
Oral
Once daily
Integrase inhibitor + CYP3A inhibitor + nucleoside/nucleotide analog reverse transcriptase inhibitors
Indications
- HIV Infections
- HIV Infections
Dosing
HIV Infections - adults and pediatric >= 25 kg One tablet (50 mg BIC/200 mg FTC/25 mg TAF) taken orally once daily with or without food; on hemodialysis days, administer after hemodialysis completion.
HIV Infections - pediatric 14 kg to < 25 kg One tablet (30 mg BIC/120 mg FTC/15 mg TAF) taken orally once daily with or without food.
HIV Infections - virologically-suppressed pregnant individuals One tablet (50 mg BIC/200 mg FTC/25 mg TAF) taken orally once daily with or without food; monitor viral load closely due to lower drug exposures during pregnancy.
HIV Infections One tablet (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg) taken orally once daily with food in adults and pediatric patients 12 years of age and older with body weight at least 35 kg and creatinine clearance >=70 mL/min.
Contraindications
- Co-administration with dofetilide due to potential for increased dofetilide plasma concentrations and serious or life-threatening events
- Co-administration with rifampin due to substantially decreased BIC plasma concentrations, which may result in loss of therapeutic effect and development of resistance
- Coadministration with alfuzosin
- Coadministration with carbamazepine, phenobarbital, or phenytoin
- Coadministration with rifampin
- Coadministration with lurasidone or pimozide
- Coadministration with dihydroergotamine, ergotamine, or methylergonovine
- Coadministration with St. John's wort (Hypericum perforatum)
- Coadministration with lomitapide, lovastatin, or simvastatin
- Coadministration with sildenafil when used for pulmonary arterial hypertension
- Coadministration with triazolam or orally administered midazolam
Adverse Reactions
Most common (>=5%) Diarrhea, nausea, headache
Serious Severe acute exacerbations of hepatitis B, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome, angioedema, Stevens-Johnson syndrome/toxic epidermal necrolysis, urticaria, weight increased
Most common (>=5%) Diarrhea, nausea, headache, fatigue
Serious Severe acute exacerbations of hepatitis B in coinfected patients, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis, bone loss and mineralization defects, immune reconstitution syndrome
Postmarketing Allergic reactions including angioedema, lactic acidosis, hypokalemia, hypophosphatemia, dyspnea, pancreatitis, increased amylase, abdominal pain, hepatic steatosis, hepatitis, increased liver enzymes, rash, rhabdomyolysis, osteomalacia, muscular weakness, myopathy, acute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis, nephrogenic diabetes insipidus, renal insufficiency, increased creatinine, proteinuria, polyuria, asthenia
Pharmacology
BIKTARVY is a fixed-dose combination antiretroviral containing bictegravir (BIC), an integrase strand transfer inhibitor (INSTI) that blocks integration of HIV-1 DNA into host genomic DNA, plus emtricitabine (FTC) and tenofovir alafenamide (TAF), both nucleoside analog reverse transcriptase inhibitors (NRTIs) that terminate viral DNA chain elongation by competing with natural nucleoside substrates.
STRIBILD is a fixed-dose combination of elvitegravir (an integrase strand transfer inhibitor), cobicistat (a CYP3A inhibitor that boosts elvitegravir levels), emtricitabine (a nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Biktarvy
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Stribild
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Biktarvy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Stribild
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (3/8) · Qty limit (5/8)
Humana
Biktarvy
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Stribild
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BiktarvyView full Biktarvy profile
StribildView full Stribild profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.